14 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 14 of 14 clinical reviews.
Evidence-based comparison of alendronate (Fosamax) and romosozumab (Evenity) for osteoporosis, including ARCH trial head-to-head data, fracture reduction rates, and clinical guidance on sequencing.
A detailed comparison of Fosamax (alendronate) and Evenity (romosozumab) side effects, including GI tolerability, cardiovascular risk, ONJ, atypical fractures, and clinical guidance on switching.
A clinical comparison of alendronate (Fosamax) and romosozumab (Evenity) for osteoporosis, including when to switch, which to use first, and what the evidence from FIT and ARCH actually shows.
Compare Fosamax (alendronate) and Prolia (denosumab) for osteoporosis: fracture reduction data from FIT and FREEDOM trials, BMD gains, onset of action, and which drug fits which patient.
A clinical comparison of alendronate (Fosamax) and denosumab (Prolia) for osteoporosis, with evidence-based guidance on when and how to switch between these two therapies.
A clinical comparison of alendronate (Fosamax) and zoledronic acid (Reclast) covering efficacy data, pricing, insurance coverage, generic availability, and practical access considerations for osteoporosis treatment.
Evidence-based comparison of alendronate (Fosamax) and zoledronic acid (Reclast) for osteoporosis, covering fracture reduction, BMD gains, dosing, side effects, and switching protocols.
Fosamax vs Reclast: Fosamax's main side effects are GI (reflux, esophageal irritation); Reclast's is a flu-like reaction after infusion, gone in 72 hours.
Evidence-based comparison of alendronate (Fosamax) and zoledronic acid (Reclast) for osteoporosis, including when and how to switch between these bisphosphonates.
Clinical comparison of denosumab and romosozumab for osteoporosis, including when and how to switch between them, trial data from FREEDOM and ARCH, and sequencing strategies to protect bone density.
A direct comparison of zoledronic acid (Reclast) and romosozumab (Evenity) covering efficacy, cost, insurance access, administration, and which patients benefit most from each drug.
A clinical comparison of the side-effect profiles of zoledronic acid (Reclast) and romosozumab (Evenity) for osteoporosis, including cardiovascular signals, acute-phase reactions, injection-site events, and rare skeletal risks.
A clinical comparison of side effects between Reclast (zoledronic acid) and Prolia (denosumab) for osteoporosis, including acute-phase reactions, rebound fracture risk, ONJ, and long-term safety data from HORIZON-PFT and FREEDOM trials.
Clinical comparison of Reclast (zoledronic acid) and Prolia (denosumab) for osteoporosis, including when and how to switch between these two bone-loss therapies safely.